Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.
Heald, R., Bowman, K.K., Bryan, M.C., Burdick, D., Chan, B., Chan, E., Chen, Y., Clausen, S., Dominguez-Fernandez, B., Eigenbrot, C., Elliott, R., Hanan, E.J., Jackson, P., Knight, J., La, H., Lainchbury, M., Malek, S., Mann, S., Merchant, M., Mortara, K., Purkey, H., Schaefer, G., Schmidt, S., Seward, E., Sideris, S., Shao, L., Wang, S., Yeap, K., Yen, I., Yu, C., Heffron, T.P.(2015) J Med Chem 58: 8877-8895
- PubMed: 26455919 
- DOI: 10.1021/acs.jmedchem.5b01412
- Primary Citation of Related Structures:  
5CAL, 5CAN, 5CAP, 5CAO, 5CAQ, 5CAS, 5CAV, 5CAU, 5C8K, 5C8M - PubMed Abstract: 
Because of their increased activity against activating mutants, first-generation epidermal growth factor receptor (EGFR) kinase inhibitors have had remarkable success in treating non-small-cell lung cancer (NSCLC) patients, but acquired resistance, throu ...